Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of “Hold” by Analysts

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) have been given a consensus recommendation of “Hold” by the five research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.00.

Several equities research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Weiss Ratings restated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 15th.

Gyre Therapeutics Stock Down 1.7%

GYRE opened at $8.28 on Monday. The stock’s 50 day moving average price is $7.68 and its two-hundred day moving average price is $7.74. The firm has a market capitalization of $797.61 million, a P/E ratio of 276.09 and a beta of 1.97. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $13.75.

Institutional Trading of Gyre Therapeutics

A number of hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue acquired a new stake in shares of Gyre Therapeutics during the 3rd quarter worth approximately $38,000. Bank of America Corp DE lifted its position in Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the period. JPMorgan Chase & Co. boosted its stake in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Gyre Therapeutics in the 4th quarter valued at $77,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.